Recurrence and survival rates of inflammatory bowel disease-associated colorectal cancer following postoperative chemotherapy:a comparative study

作     者：Mohannad Dugum Jingmei Lin Rocio Lopez Bassam Estfan Elena Manilich Luca Stocchi Bo Shen Xiuli Liu 

作者机构：Division of GastroenterologyHepatology and NutritionDepartment of MedicineUniversity of PittsburghPittsburghPAUSA Department of Pathology and Laboratory MedicineIndiana University School of MedicineIndianapolisINUSA Quantitative Health SciencesCleveland ClinicClevelandOHUSA Department of Hematology and OncologyTaussig Cancer InstituteCleveland ClinicClevelandOHUSA Department of Colorectal SurgeryDigestive Disease InstituteCleveland ClinicClevelandOHUSA Department of Gastroenterology and HepatologyDigestive Disease InstituteCleveland ClinicClevelandOHUSA Department of Anatomic PathologyPathology&Laboratory Medicine InstituteCleveland ClinicClevelandOHUSA 

出 版 物：《Gastroenterology Report》 (胃肠病学报道（英文）)

年 卷 期：2017年第5卷第1期

页      面：57-61,I0002,I0003页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：inflammatory bowel disease colorectal cancer adjuvant chemotherapy prognosis 

摘      要：Background and Aim:Inflammatory bowel disease(IBD)is associated with an increased risk of colorectal cancer(CRC).Studies have shown tumorigenetic and histomorphological differences between IBD-associated CRC and non-IBD CRC,suggesting differences in tumor behavior and response to *** aimed to compare tumor recurrence and survival rates following postoperative chemotherapy in CRC patients with and without ***:Search of the Cleveland Clinic’s CRC database revealed 65 patients who had IBD-associated CRC and received postoperative adjuvant chemotherapy between 1994 and ***-one patients were excluded due to incomplete clinical *** score-matching based on age,surgery intent,CRC site,tumor grade,American Joint Committee on Cancer(AJCC)stage and T stage was used to match IBD and non-IBD patients(1:4).Competing risk and Cox regression models were used to analyze differences in disease-free survival and overall survival,***:Forty-four patients with IBD-associated CRC were matched to 176 patients with non-IBD *** IBD patients,29(66%)had ulcerative colitis,14(32%)had Crohn’s disease,and one(2%)had indeterminate *** IBD diagnosis age was 28.1±14.5 years,and mean IBD duration at time of CRC treatment was 21.5±12.6 ***(23%)IBD patients had tumor recurrence compared with 34(19%)non-IBD patients(P=.074).There was no significant difference in disease-free survival(hazard ratio[HR]=0.60;95%CI:0.35–1.05;P=0.074)or overall survival(HR=0.87;95%CI:0.54–1.4;P=0.58)between IBD and non-IBD ***:Patients with IBD-associated CRC have comparable rates of tumor recurrence and survival following postoperative chemotherapy as CRC patients without *** studies are needed to confirm these findings and guide therapeutic decisions.